All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
FDA’s Center for Drug Evaluation and Research’s (CDER) Office of Compliance
By Mark Land, M.S., RAC, AAHP President The Office of Compliance (OC) shields patients from poor quality, unsafe, and ineffective drugs through compliance strategies and...
Meet Jill Furman, JD, New Director of FDA’s Office of Compliance
Drug evaluation and research help to ensure drug quality and therefore, public safety. Leading the charge in this critical mission is Jill Furman, J.D., the...
FDA Office of Compliance Annual Report FY 2022
FDA's Office of Compliance (OC) recently published its Annual Report for Fiscal Year 2022.1 The report was introduced by Director Jill Furman. Ms. Furman took...
Snapshots from There and Then: History of Homeopathy
In honor of AAHP's 100th anniversary year, we're looking back at the history of homeopathy to learn how the medical modality spread worldwide. Readers will...
Compliance Makes All the Difference
By Mark Land, M.S., RAC, AAHP President The May issue of the AAHP newsletter examined the work of the Federal Trade Commission (FTC) while this...
Meet HPCUS President William Shevin
Published since 1897, the Homeopathic Pharmacopoeia of the United States (HPUS) provides a clear set of standards and guidelines for the manufacturer of homeopathic drug products. Since...
Revised HPUS Website to Launch in June
By Eric L. Foxman, Senior Scientist, HPCUS The revised and updated HPUS.com for the Homeopathic Pharmacopeia of the United States will tentatively be launched June 5. The newly designed...
